 Home > Chemical News > Pharma News

Pharma News

: Johnson & Johnson Ends Partnership With Bavarian Nordic on Hepatitis B and HPV Vaccines

On May 9, Johnson & Johnson announced that it had terminated its partnership and licensing agreement with Bavarian Nordic.

Bavarian Nordic HPV vaccine
2022-05-10

: The Latest Development of Oral COVID-19 Vaccine May Reduce the Risk of Virus Airborne Transmission

At present, the vast majority of new crown vaccination methods are intramuscular injection.

oral COVID-19 vaccine
2022-05-09

: Amylyx Announces Latest Statistical Analysis of New ALS Drugs

Recently, Amylyx announced the results of the long-term survival analysis of AMX0035 in the treatment of amyotrophic lateral sclerosis (ALS) phase 2 CENTAUR trial adjusted for placebo crossover.

Amylyx ALS drug
2022-05-09

: Are More "Vitamins" in The Feed the Better?

Vitamin, also known as vitamin, is a life-sustaining substance, is a kind of trace organic substances necessary to maintain the normal physiological function and life activities of animals

vitamin feed
2022-05-09

: Novartis Suspends Production of Two Radioligand Drugs Due to Potential Quality Issues

Novartis announced on Thursday that it has suspended production of neuroendocrine tumor treatment Lutathera and recently FDA-approved prostate cancer treatment Pluvicto at its plants in Ivrea, Italy and Milburn, New Jersey.

Novartis Radioligand drug
2022-05-07

: Three Months Extension! FDA Delays Pfizer's Myfembree Supplemental New Drug Application

Just a month ago, the US FDA expressed concern about the supplemental new drug application for the drug Myfembree (relugolix) jointly developed by Pfizer and Myovant Sciences.

FDA Pfizer Myfembree
2022-05-07

: FDA Withdraws Accelerated Approval for Bristol-Myers Squibb's PTCL Indication for Romidepsin

On May 6, the U.S. FDA officially announced that it had withdrawn the approval of Bristol-Myers Squibb’s Istodax (romidepsin, romidepsin) for peripheral T-cell lymphoma (PTCL) indications.

FDA Romidepsin
2022-05-07

: The Global Pharmaceutical Innovation Index is released!

A few days ago, IDEA Pharma, a British pharmaceutical consulting company, released the 2022 Pharmaceutical Innovation Index and Pharmaceutical Invention Index rankings.

semaglutide dose
2022-05-07

: API: Industrial Upgrading, Industrial Extension

As always, the 14th Five-Year Plan emphasises the green development of the API industry, pointing out that as the pharmaceutical industry moves towards a new stage of development

API CDMO
2022-05-06

: Global Pharmaceutical Innovation: Adhere to Open Development, Win-win Cooperation

The "14th Five-Year Plan" emphasizes the adherence to open development, win-win cooperation, and an active response to global pharmaceutical innovation

pharmaceutical innovation
2022-05-06

: Clinical Usage and Compatibility of Doxycycline Hydrochloride

Doxycycline hydrochloride, also known as doxycycline hydrochloride and deoxyoxytetracycline, is a tetracycline antibiotic with broad-spectrum antibacterial activity, but its antibacterial activity is 2-10 times higher than that of oxytetracycline.

Doxycycline hydrochloride
2022-05-06

Go to Page

Hot News



ECHEMI Partner





Suggestions

Email:

Message:

Send Message